Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes
NCT06082063 on ClinicalTrials.gov · last registry update 2025-01-10
An unusually large phase 3: 2,000 participants, more than double the 424 typical for the stage. Due to report 1 July 2029, alongside 12 other tracked readouts that quarter. Primary outcome, as filed: MACE + HHF. Sponsors move these dates routinely; any movement since this site started watching is listed below. It has been running since 1 July 2024 — 2 years so far. semaglutide is approved in the US, but not for heart failure and type 1 diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- RECRUITING
- Phase
- P3
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor
- Steno Diabetes Center Copenhagen
- Sponsor type
- Other
- Enrollment
- 2,000
- Started
- 2024-07-01
- Primary completion
- 2029-07-01 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
MACE + HHF
Conditions studied
Cardiovascular Diseases · Heart Failure · Type 1 Diabetes · Kidney Failure
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.